On Monday July 6, Johnson & Johnson announced a price reduction of the anti-tuberculosis medicine bedaquiline, for low- and middle-income countries. Thanks to the support of USAID and the Global Fund, this price reduction could be achieved. The price dropped from $400 to $340 for a six-month treatment regimen.